You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Dow
AstraZeneca
Mallinckrodt
Medtronic

Last Updated: April 19, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AMYVID

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Amyvid

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00702143 A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) Completed Avid Radiopharmaceuticals Phase 2 2008-06-01 Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
NCT00857415 Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain Completed Avid Radiopharmaceuticals Phase 3 2008-12-01 The study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid by dissection of the brain at autopsy. Amyloid in the brain is a key feature of Alzheimer's Disease (AD).
NCT00857532 Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 2 2009-01-01 The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.
NCT00857532 Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients Completed National Institutes of Health (NIH) Phase 2 2009-01-01 The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.
NCT00857532 Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients Completed Avid Radiopharmaceuticals Phase 2 2009-01-01 The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.
NCT01400425 Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline Completed Avid Radiopharmaceuticals Phase 3 2011-07-01 The study is designed to evaluate whether a florbetapir F 18 PET scan can impact clinical thinking when physicians are determining the likely cause of a subject's cognitive impairment.
NCT01518374 Clinical Evaluation of Florbetapir F 18 (18F-AV-45) Recruiting Avid Radiopharmaceuticals Phase 2 2009-12-01 This protocol is designed to standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden in subjects participating in other studies (companion protocol) such as longitudinal studies of aging and studies of biomarkers for neurodegenerative diseases.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Amyvid

Condition Name

Condition Name for Amyvid
Intervention Trials
Alzheimer's Disease 16
Alzheimer Disease 8
Mild Cognitive Impairment 5
Frontotemporal Dementia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Amyvid
Intervention Trials
Alzheimer Disease 27
Cognition Disorders 7
Mild Cognitive Impairment 5
Dementia 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Amyvid

Trials by Country

Trials by Country for Amyvid
Location Trials
United States 125
Canada 6
Italy 5
Australia 5
Spain 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Amyvid
Location Trials
California 12
Florida 11
Pennsylvania 10
New York 8
Connecticut 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Amyvid

Clinical Trial Phase

Clinical Trial Phase for Amyvid
Clinical Trial Phase Trials
Phase 4 6
Phase 3 4
Phase 2/Phase 3 2
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Amyvid
Clinical Trial Phase Trials
Completed 21
Recruiting 6
Active, not recruiting 4
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Amyvid

Sponsor Name

Sponsor Name for Amyvid
Sponsor Trials
Avid Radiopharmaceuticals 25
Eli Lilly and Company 4
Molecular NeuroImaging 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Amyvid
Sponsor Trials
Industry 34
Other 11
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Colorcon
McKesson
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.